EU MDR tender requirements: what changed in 2026 and what it means for your next bid

15 April 2026

The EU Medical Device Regulation (MDR 2017/745) transition period has been the regulatory equivalent of a slow-motion train wreck. Extensions, grace periods, and "just one more year" pushed the deadlines further and further. In 2026, the train arrived. Here's what it means for your tender responses.

What actually changed

Three things happened in 2026 that directly affect tender compliance:

1. MDD certificates expired for most device classes

The extended transition period for Class IIa, IIb, and III devices under the Medical Devices Directive (MDD 93/42/EEC) reached its final deadline. Devices that were still on the market under MDD certificates needed to either:

Have an MDR conformity assessment completed, or
Have a valid application lodged with a Notified Body before the cutoff date

For tender response teams, this means one thing: your compliance matrix needs to reference MDR, not MDD. A tender submission that cites an MDD certificate for a device that should be under MDR will be flagged — and likely disqualified.

2. Notified Body certificates now require MDR Annex references

Under MDD, a Notified Body certificate was relatively straightforward. Under MDR, certificates must reference specific conformity assessment procedures (Annex IX, X, or XI), include the device's Unique Device Identification (UDI), and specify any conditions or limitations.

Tender evaluators in EU member states are now checking these details. A generic "CE certificate" without the MDR-specific references is insufficient.

3. Post-market surveillance became a tender criterion

MDR Article 83 requires manufacturers to establish a Post-Market Surveillance (PMS) system proportionate to the risk class. This was always a regulatory requirement, but in 2026, procurement frameworks started including PMS capability as an evaluation criterion.

Concretely, this means tenders now ask for:

A summary of your PMS plan for the tendered device
Evidence of periodic safety update reports (PSUR) or post-market clinical follow-up (PMCF)
A description of your vigilance and complaint handling process

How to update your compliance matrix

If your compliance matrix still references MDD, here's a practical update checklist:

Step 1: Audit your certificate inventory

List every product you tender. For each one, verify: Does the current certificate reference MDR 2017/745? If it references MDD 93/42/EEC, check whether a valid MDR application is in progress.

Step 2: Update regulatory evidence files

For each product with an MDR certificate, ensure your evidence library includes:

EU Declaration of Conformity referencing MDR
Notified Body certificate with Annex reference and UDI
EUDAMED registration (when available)
Summary of Safety and Clinical Performance (SSCP) for Class III and implantable devices

Step 3: Add PMS documentation

Create a tender-ready PMS summary document. This doesn't need to be your full PMS plan (that's a confidential regulatory document). It should be a structured summary showing:

Complaint handling process overview
Vigilance reporting compliance
PMCF study status (if applicable)
Most recent PSUR date

Step 4: Automate the cross-reference

With 14 regulatory regimes worldwide and transition timelines that vary by device class, manual tracking is a formula for missed deadlines and expired certificates in your submissions. Automated regulatory cross-referencing — checking certificate validity in real time against the tender's target market — is no longer optional for teams tendering across multiple EU member states.

The competitive angle

Here's what most teams miss: MDR compliance is not just a pass/fail gate. It's a competitive differentiator. Teams that can demonstrate a complete MDR evidence chain — certificate, UDI, PMS plan, SSCP — score higher than teams that submit the bare minimum. Tender evaluators notice the difference between "we're compliant" and "here's the evidence, the audit trail, and the ongoing surveillance plan."

The teams that treat MDR transition as a compliance burden will survive. The teams that treat it as a quality signal will win.